V

Vijaya Diagnostic Centre Limited

VIJAYANSE
Market snapshot · 2026-08-12 12:16 UTC

1,510.60

+₹82.40 (+5.77%)

MARKET CAP

₹15.56K Cr

STOCK P/E

83.3x

52W HIGH

₹1,525.00

52W LOW

₹848.00

BOOK VALUE

₹93.06

EPS

₹18.14

ROE

SECTOR

Health Care

DEBT/EQUITY

44.15

VOLUME

14.00L

P/B RATIO

16.23x

PEG RATIO

2.10

Sector

Health Care

Themes

Hospitals & Diagnostic Centres
D
Dividend
E
Earnings
₹1,464.10₹1,315.65₹1,167.20₹1,018.75₹870.30VolumeDEEEEAug '25Sep '25Nov '25Jan '26Mar '26Apr '26Jun '26Aug '26

AI Summary

✦ Clartha

Vijaya Diagnostic Centre is an Indian diagnostic services provider serving patients through laboratory and imaging businesses. Laboratory services span pathology, microbiology, biochemistry, molecular diagnostics, and histopathology, while imaging includes CT, MRI, ultrasound, X-ray, and PET/CT. Health checkups and home sample collection broaden access and support volume growth. Revenue increased 19.5% year-on-year, with stable margins indicating growth has not yet required material profitability concessions. Profit grew 20.3%, modestly ahead of revenue, but ROE is unavailable for assessing capital efficiency. Debt/equity of 44.15 indicates extreme leverage, potentially magnifying reported shareholder returns and increasing balance-sheet sensitivity. At 83.3x earnings, the shares appear rich relative to a roughly 20% growth rate, implying investors already price sustained expansion. The valuation remains exposed to execution, competitive pricing, and the need to convert network growth into higher margins.

Forecast

Analyst targets, estimate history, and probabilistic forward ranges for VIJAYA.

10.00 analysts

Price Forecast

Current
₹1,511
High Target
₹1,700
▲ +12.5%
Median Target
₹1,540
▲ +1.9%
Low Target
₹1,300
▼ -13.9%
Now₹1,511High ₹1,700Median ₹1,540Low ₹1,300Aug '25Now12M Target
Price history (1Y)
Analyst target range
10 analysts

Probabilistic Range

Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.

Time horizonRange ()Probability
3M₹1,263 - ₹1,88780%
6M₹1,188 - ₹2,09780%
12M₹1,103 - ₹2,46480%
Realized vol: +31.4% · Drift: +13.7%

Revenue Forecast

₹ Cr
Dec '25Current₹193.0
Sep 2026 ETrend estimate range
High₹244.6Base₹226.5Low₹208.4
Mar '25: ₹160.0 · Jun '25: ₹177.0 · Sep '25: ₹189.0 · Dec '25: ₹193.0 · Sep '26: ₹226.5 · Dec '26: ₹231.3
Mar '25Jun '25Sep '25Dec '25Sep '26 EDec '26 E160.0177.0189.0193.0226.5231.3
PastCurrentTrend estimate: Low / Base / High

EPS Forecast

₹ / share
Dec '25Current₹4.30
Sep 2026 ETrend estimate range
High₹5.77Base₹5.15Low₹4.53
Mar '25: ₹3.23 · Jun '25: ₹3.76 · Sep '25: ₹4.15 · Dec '25: ₹4.30 · Sep '26: ₹5.15 · Dec '26: ₹5.34
Mar '25Jun '25Sep '25Dec '25Sep '26 EDec '26 E3.233.764.154.305.155.34
PastCurrentTrend estimate: Low / Base / High
Market Intelligence

Multi-factor synthesis of 5 key dimensions

Overall Outlook
Mixed
51%
Analyst Consensus
Positive

From 10 analysts

Mean upside+1.3%

Fundamentals

Strong

Fundamentals institutional score is 94 using growth durability 93.7.

Valuation

Premium valuation

Valuation institutional score is 14 using relative multiple z-scores where peer dispersion is available.

Analyst Consensus

Neutral

Analyst View institutional score is 62 using mean target upside 1.3%; dispersion penalty 10.5; recommendation breadth from available consensus.

Technical Structure

Weak Structure

Technicals institutional score is 14 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.

Market Sentiment

Neutral backdrop

Recent news flow is balanced or not decisive enough to tilt the tape. Based on 10 recent ticker-linked news items.

Signal Summary

Market intelligence remains Mixed. fundamentals provide support, while valuation and technical structure remain considerations.

Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.

Fundamentals StrongValuation Premium valuationAnalyst Consensus NeutralTechnical Structure Weak StructureMarket Sentiment Neutral backdrop

Key Data Points

Mean Target Price1,530.3 target
Mean Upside+1.3%
Technical Score14%
Fundamental Score94%
Data CoverageHigh

Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.

Valuation Metrics

Trading 49.3% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.39). Confidence: 75%.

Live forward EPS implies next-12-month EPS of ₹27.46. Applying the stock's normalized valuation corridor produces a fair range of ₹1,112.40 to ₹1,524.30, with base value near ₹1,439.73 (-1.7% vs current price).

Forward Valuation Outlook

Live forward estimate anchored to the company's historical valuation corridor.

Inside normalized range

Forward EPS

₹27.46

Forward P/E

53.3x

Base Fair Value

₹1,439.73

Fair Range

₹1,112.40 - ₹1,524.30

Upside To Base

-1.7%

Estimate Source

Live forward EPS

Growth Estimate

+37.3%

P/E
Strongly Overvalued

5Y Average

39.85

Current

78.25

Overvalued

55.51

Undervalued

40.51

EV/EBITDA
Strongly Overvalued

5Y Average

20.35

Current

39.97

Overvalued

27.25

Undervalued

12.45

P/S
Strongly Overvalued

5Y Average

8.96

Current

17.59

Overvalued

12.00

Undervalued

5.48

Peers & Comparison

Sector: Health Care · Theme: Hospitals & Diagnostic Centres

Hospitals & Diagnostic Centres Peers8 peers
Avg P/E: 82.9x
CompanyRev. GrowthMarginP/Evs Avg52W Perf.
METROPOLIS HEALTHCARE LTD
METROPOLISHospitals & Diagnostic Centres
+16.6%11.8%
56.7x
Undervalued
-32% vs avg
+6.6%
FORTIS HEALTHCARE LTD
FORTISHospitals & Diagnostic Centres
+17.5%11.0%
65.0x
Undervalued
-22% vs avg
-1.1%
GLOBAL HEALTH LIMITED
MEDANTAHospitals & Diagnostic Centres
+26.5%11.9%
67.6x
Undervalued
-18% vs avg
+6.3%
NEPHROCARE HEALTH SERV L
NEPHROPLUSHospitals & Diagnostic Centres
+22.2%8.1%
83.9x
Fair
+1% vs avg
+51.2%
JUPITER LIFE LINE HOSP L
JLHLHospitals & Diagnostic Centres
+18.2%12.0%
53.5x
Undervalued
-35% vs avg
+7.8%
ASTER DM QUALITY CARE LTD
ASTERDMHospitals & Diagnostic Centres
+21.6%6.5%
134.4x
Premium
+62% vs avg
+39.5%
NARAYANA HRUDAYALAYA LTD.
NHHospitals & Diagnostic Centres
+80.4%9.0%
45.2x
Undervalued
-45% vs avg
+1.0%
KRISHNA INST OF MED SCI L
KIMSHospitals & Diagnostic Centres
+35.3%4.8%
157.0x
Premium
+89% vs avg
+11.2%
WHY THESE PEERS

VIJAYA DIAGNOSTIC CEN LTD trades in line with peers (83.3x vs avg 82.9x), reflecting a fair valuation within the Hospitals & Diagnostic Centres cohort. Peers include METROPOLIS HEALTHCARE LTD, FORTIS HEALTHCARE LTD, GLOBAL HEALTH LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹193 CrDec 2025

Latest net profit

₹44 CrDec 2025

Latest EPS

₹4.30Dec 2025

Net margin

31.8%Dec 2025

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q3 '25Q4 '25Q1 '26Q2 '26Q3 '260.0%8.0%16.0%24.0%32.0%0.00 Cr50 Cr100 Cr150 Cr200 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q3 '25Q4 '25Q1 '26Q2 '26Q3 '260.00 Cr50 Cr100 Cr150 Cr200 Cr₹0₹2₹4₹6₹8
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOperatingprofitOther incomeInterestProfitbefore taxTax & otherNet Profit0.00 Cr50 Cr100 Cr150 Cr200 Cr

Latest reported period: Dec 2025

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
202120222023202420250.00 Cr50 Cr100 Cr150 Cr200 Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

MetricMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales118119136129141142170156160177189193
Expenses70.2471.2479.7678.0383.886.799.7393.7995.7107111110
Operating Profit36.7735.0542.7136.6942.3440.5355.3545.6147.0451.7359.1161.43
OPM %31.07%29.52%31.37%28.42%30.02%28.46%32.47%29.19%29.43%29.27%31.22%31.82%
Other Income4.535.866.925.253.413.834.64.995.687.235.155.55
Interest5.765.875.846.055.956.056.076.266.586.917.217.95
Depreciation11.3212.4413.6614.414.9115.1915.416.8617.1118.3619.421.25
Profit before tax35.5435.0443.7935.8939.838.3153.8844.3446.1452.0557.0559.03
Tax %24.25%25.8%24.98%23.93%23.34%24.67%26.22%24.38%25.99%25.55%25.15%25.11%
Net Profit26.922632.8527.330.5128.8639.7533.5334.1538.7542.744.21
EPS in Rs2.642.553.212.472.982.823.873.263.233.764.154.30

All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.

Shareholding Pattern

HolderMar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters53.05%52.63%52.60%52.60%52.51%
FII19.36%19.56%18.27%15.10%13.38%
DII23.72%24.07%25.34%28.60%29.93%
Public3.42%3.24%3.20%3.14%3.47%
Others0.45%0.50%0.59%0.56%0.71%
Mar 2026
Promoters
FII
DII
Public
Others

Events Timeline

Concall Transcript - FY2027

Jul 29, 2026PDFKnowledge Base Open

Concall Transcript - FY2027

Jul 28, 2026PDFKnowledge Base Open

Concall Transcript - FY2027

Jun 09, 2026PDFKnowledge Base Open

Concall Transcript - FY2027

May 13, 2026PDFKnowledge Base Open

Concall Transcript - FY2027

May 12, 2026PDFKnowledge Base Open